EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells

Prerona Bora iD, Mashiat Zaman iD, Samantha Oviedo, Sergei Kutseikin, Nicole Madrazo iD, Prakhyat Mathur iD, Meera Pannikkat iD, Sophia Krasny, Rama Aldakhlallah iD, Alan Chu iD, Kristen A Johnson iD, Danielle A Grotjahn iD und 2 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2517552122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Prerona Bora und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037. Hauptthemen laut MEDLINE: Mitochondria, GTP Phosphohydrolases, Drug Repositioning, Mitochondrial Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH (NIH), Canadian Institutes of Health Research (CIHR), NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogenic variants in the mitochondrial outer membrane GTPase MFN2 cause the peripheral neuropathy Charcot–Marie–Tooth type 2A (CMT2A). These mutations can disrupt MFN2-dependent regulation of diverse aspects of mitochondrial biology including organelle morphology, motility, mitochondrial-endoplasmic reticulum (ER) contacts (MERCs), and respiratory chain activity. However, no therapies currently exist to mitigate the mitochondrial dysfunction linked to genetic deficiencies in MFN2. Herein, we performed a drug repurposing screen to identify compounds that selectively activate the integrated stress response (ISR)—the predominant stress-responsive signaling pathway responsible for regulating mitochondrial morphology and function. This screen identified the compounds parogrelil and MBX-2982 as potent and selective activators of the ISR through the OMA1-DELE1-HRI signaling axis. We show that treatment with these compounds promotes adaptive, ISR-dependent remodeling of mitochondrial morphology and protects mitochondria against genetic and chemical insults. Moreover, we show that pharmacologic ISR activation afforded by parogrelil restores mitochondrial tubular morphology, promotes mitochondrial motility, rescues MERCs, and enhances mitochondrial respiration in MFN2 -deficient cells. These results demonstrate the potential for pharmacologic ISR activation through the OMA1-DELE1-HRI signaling pathway as a potential strategy to mitigate mitochondrial dysfunction in CMT2A and other pathologies associated with MFN2 deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaGTP PhosphohydrolasesDrug RepositioningMitochondrial ProteinsCharcot-Marie-Tooth DiseaseAnimalsHumansSignal TransductionMice

Stichwörter der Autor:innen

drug repurposingintegrated stress responsemitochondrial dysfunction

Substanzen

GTP PhosphohydrolasesMitochondrial ProteinsMFN2 protein, humanMfn2 protein, mouse

Autor:innen und Institutionen

  • Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.
  • Department of Biochemistry and Molecular Biology, Cummings School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.
  • Calibr-Skaggs Institute for Innovative Medicines, The Scripps Research Institute, La Jolla, CA 92037.
  • Department of Medical Genetics, Cumming School of Medicine, Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB T2N 4N1, C…
  • Department of Biochemistry and Molecular Biology, Cumming School of Medicine, Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, Alberta Children's Hospital Research Institute, University of Calgary, Calg…

ORCID-Profile: Prerona Bora, Mashiat Zaman, Nicole Madrazo, Prakhyat Mathur, Meera Pannikkat, Rama Aldakhlallah, Alan Chu, Kristen A Johnson, Danielle A Grotjahn, R Luke Wiseman

Förderung

  • HHS | NIH (NIH)
  • Canadian Institutes of Health Research (CIHR)
  • NIA NIH HHS
  • American Heart Association (AHA)
  • Wellcome Trust
  • NINDS NIH HHS
  • HHS | NIH | National Institute on Aging (NIA)
  • Hotchkiss Brain Institute International Graduate Recruitment Scholarship

Zitieren

APA

Bora, P., Zaman, M., Oviedo, S., Kutseikin, S., Madrazo, N., Mathur, P., Pannikkat, M., Krasny, S., Aldakhlallah, R., Chu, A., Johnson, K. A., Grotjahn, D. A., Shutt, T. E., & Wiseman, R. L. (2025). Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2517552122

Vancouver

Bora P, Zaman M, Oviedo S, Kutseikin S, Madrazo N, Mathur P, et al. Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2517552122

BibTeX
@article{Bora2025,
  author = {Bora, Prerona and Zaman, Mashiat and Oviedo, Samantha and Kutseikin, Sergei and Madrazo, Nicole and Mathur, Prakhyat and Pannikkat, Meera and Krasny, Sophia and Aldakhlallah, Rama and Chu, Alan and Johnson, Kristen A and Grotjahn, Danielle A and Shutt, Timothy E and Wiseman, R Luke},
  title = {Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2517552122}
}
Kostenlos starten →